Austria 2 – 1 N Ireland

first_imgFTFull TimeAETAfter Extra TimeLIVEThis is a live match.ETExtra TimeHTHalf Time – Advertisement – 7:45pm, Sunday 15th November 2020.Ernst-Happel-Stadion.center_img Austriavs Northern Ireland. UEFA Nations League Group B1.- Advertisement –last_img

England: Raheem Sterling and Jordan Henderson out of Nations League clash vs Iceland | Football News

first_imgVisit skysports.com or the Sky Sports App for all the breaking sports news headlines. You can receive push notifications from the Sky Sports app for the latest news from your favourite sports and you can also follow @SkySportsNews on Twitter to get the latest updates. – Advertisement – Raheem Sterling and Jordan Henderson have been ruled out of England’s Nations League clash with Iceland on Wednesday because of injury.More to follow…- Advertisement –center_img This is an England breaking news story that is being updated and more details will be published shortly. Please refresh this page for the latest updates.Sky Sports brings you live updates as they happen. Get breaking sports news, analysis, exclusive interviews, replays and highlights.Sky Sports is your trusted source for breaking sports news headlines and live updates. Watch live coverage of your favourite sports: Football, F1, Boxing, Cricket, Golf, Tennis, Rugby League, Rugby Union, NFL, Darts, Netball and get the latest transfers news, results, scores and more.- Advertisement –last_img read more

With H1N1 resistance, CDC changes advice on flu drugs

first_imgDec 19, 2008 (CIDRAP News) – Increased resistance to oseltamivir (Tamiflu), the leading influenza drug, has prompted federal health officials to change their advice about flu treatment, saying clinicians for now should consider using zanamivir (Relenza) or a combination of two drugs for patients suspected of having influenza A.The Centers for Disease Control and Prevention (CDC) today said 49 of 50 influenza A/H1N1 viruses tested so far this season have shown resistance to oseltamivir. But all the isolates remained sensitive to zanamivir and to the two older flu drugs, amantadine and rimantadine.H1N1 is one of the three viral types and subtypes included in season flu vaccine; the others are A/H3N2 and B.”When influenza A (H1N1) virus infection or exposure is suspected, zanamivir or a combination of oseltamivir and rimantadine are more appropriate options than oseltamivir,” the CDC said in today’s advisory. “Local influenza surveillance data and laboratory testing can help with physician decision-making regarding the choice of antiviral agents for their patients.”But Dr. Anthony Fiore, a medical epidemiologist in the CDC’s Influenza Division, said rapid flu tests don’t identify the viral subtype, and many areas don’t have good flu surveillance data. “This problem really does complicate deciding what kind of antiviral to use,” he told CIDRAP News.At the same time, he said US flu activity remains low so far this season, and the resistant H1N1 viruses seem no more virulent than susceptible ones. In its weekly surveillance update today, the CDC said 3 states have reported local flu activity, while 36 states have reported only sporadic cases. Another 11 states have reported no flu cases yet.The CDC said vaccination should continue as the primary method for preventing the flu, as the oseltamivir-resistant H1N1 viruses are antigenically similar to the H1N1 strain in this year’s vaccine.Resistance emerged last seasonSince January 2006, oseltamivir and zanamivir have been the only antivirals recommended for flu in the United States. At that point the CDC advised clinicians to stop using amantadine and rimantadine, known as the adamantanes, because H3N2 viruses had become highly resistant to them. Today’s interim guidance puts the adamantanes back in the recommendations.Significant H1N1 resistance to oseltamivir emerged in the United States and a number of other northern hemisphere countries during the 2007-08 flu season. Overall, 10.9% of tested H1N1 viruses in this country showed resistance, according to the CDC.But resistance rose to nearly 100% in some southern hemisphere countries, particularly Australia and South Africa, in their 2008 season, said Fiore.The CDC’s new interim recommendations for healthcare providers include the following:Review local or state flu virus surveillance data weekly to determine which types and subtypes are circulating.Consider using rapid tests that can distinguish types A and B. Fiore said some rapid tests can do this, but others can’t.Patients who test positive for type B can be given either oseltamivir or zanamivir if treatment is indicated.If a patient tests positive for type A, zanamivir should be considered if treatment is indicated. Oseltamivir should be used alone only if local surveillance data suggest that circulating viruses are likely to be A/H3N2 or B. A combination of oseltamivir and rimantadine is an acceptable alternative, and may be necessary for patients who can’t take zanamivir, which is taken by inhalation and is not licensed for children younger than 7 years. Amantadine can replace rimantadine if the latter is not available.If a patient tests negative on a rapid flu test, clinicians should still consider treatment, depending on local flu activity and clinical signs and symptoms. (Fiore said rapid tests are not very sensitive and work better in children than adults.) If treatment is indicated, zanamivir or a combination of oseltamivir and rimantadine should be considered.Where available, testing for viral subtypes can guide treatment. For patients with an H3N2 or B virus, either oseltamivir or zanamivir can be used; for an H1N1 infection, zanamivir or the combination of oseltamivir and rimantadine can be used.What pushed the CDC to make the new recommendations, said Fiore, was the high level of resistance in the H1N1 viruses tested, plus the fact that most of the viruses tested so far this season have been H1N1.The latter factor could easily change, he said. “Last season at this time, H1N1 was the most common [subtype], but a month later they were a distant third place. That could happen again. So these are interim guidelines, and one hope we have is that clinicians will recognize that things are a little complicated this year and keep track of the recommendations that come out.”Fiore said polymerase chain reaction (PCR) tests that can identify flu subtypes are now available, but their use is mostly limited to specialty labs, such as state health departments. Once samples arrive at the lab, the tests take a couple of hours. “So if you were going to wait to decide therapy, you’re going to end up with a pretty substantial delay,” he said.Also, he said many areas don’t have good local flu surveillance data. “That advice to look at local data is probably not going to be useful in a lot of areas,” he commented.On the other hand, he noted, “We don’t have much flu activity of any kind right now. . . . And things could continue to evolve and change.”He added, “The fact is that most people don’t get antiviral treatment in the first place. And the resistant viruses are not any more dangerous or virulent, so the person is not going to know if they have resistant flu.”Experts air practical concernsKristine Moore, MD, MPH, medical director of the University of Minnesota Center for Infectious Disease Research and Policy, which publishes CIDRAP News, said she’s not surprised by the sudden spike in antiviral resistance in this year’s circulating H1N1 strain. She said influenza A viruses have a strong tendency to mutate rapidly, and that increasing use of oseltamivir has placed more selective pressure on the virus.The quick emergence of antiviral resistance and the CDC’s revised treatment recommendation have important implications for pandemic flu planning, Moore said. A rapid change affecting treatment could happen in a pandemic influenza strain. “This teaches us not to rely on any one strategy,” she said.William Schaffner, MD, chairman the Department of Preventive Medicine at the Vanderbilt University School of Medicine, told CIDRAP News that healthcare providers expect a little disconcerting news each flu season. “But we got the prize in the Cracker Jack box early this year,” he said.If physicians need to prescribe treatment for some of their patients who have influenza, they’re going to have to get a sense of what strains are circulating in their area, which will be a change for many practitioners.Schaffner advises physicians to use the rapid test to guide treatment. Patients who have the B strain will still benefit from oseltamivir treatment.Though the CDC recommends zanamivir as an option for treating patients who have A strains, Schaffner said many physicians aren’t as familiar with teaching patients how to use the inhaler. “Pharmacists are going to be very helpful,” he said.Some experts questioned if physicians will have enough information about what influenza subtypes are circulating in their area. Kristen Ehresmann, RN, MPH, manager of immunization, tuberculosis, and international health at the Minnesota Department of Health (MDH) in St. Paul, told CIDRAP News that many state public health laboratories have the reagents used to distinguish influenza subtypes.However, she said getting a timely picture of the circulating strains will be a challenge. Though most public health labs easily handle sentinel surveillance samples, they have a more limited ability to process randomly submitted samples.”Every state’s resources are different,” Ehresmann said, adding that the MDH uses a weekly e-mail listserv to update clinicians on the status of circulating influenza strains.Schaffner said he contacted Vanderbilt’s virus lab today and asked if they could start subtyping the influenza A strains and communicating the results to Tennessee’s health department and the general medical community.”This is new for the labs, but there is an urgency for this information,” he said. “Doctors will have to learn how to keep up with information about the circulating strains.”The experts who spoke with CIDRAP News said they were concerned about the nation’s supply of zanamivir, given the CDC’s revised antiviral recommendations. Moore said even if the supply seems adequate, some regions of the country may still experience shortages.However, GlaxoSmithKline, the maker of zanamivir, said today in a press release that it has sufficient supplies to meet the needs of the 2008-09 influenza season and that pharmacies can get the medicine from their wholesalers.Moore and Schaffner both expressed concerns about the combination (oseltamivir and rimantadine) therapy alternative recommended for patients who can’t take zanamivir. “It’s a reasonable recommendation, but its efficacy and safety have never been demonstrated in humans,” Moore said.Added impetus to vaccinateA silver lining in the CDC’s antiviral resistance warnings and treatment recommendations is that they strengthen the rationale for seasonal flu vaccination, the experts said. “These events speak to the value of vaccination and not counting on being able to treat influenza after the fact,” Ehresmann said.Schaffner, who is also president-elect of the National Foundation for Infectious Diseases, said vaccine supplies are abundant this year, and an examination of early viral isolates suggests that the vaccine is a good match with the circulating strains.This year so far looks like a typical flu season, and activity usually peaks in February, he said, “so there’s still time to be protected by getting the vaccine through December and into January.”See also:CDC interim antiviral guidance for 2008-2009CDC weekly flu surveillance updatelast_img read more

Founders, VCs call for start-ups to innovate, look for opportunities amid COVID-19

first_imgAccording to the Research and Technology Ministry’s National Research and Innovation Agency (BRIN), only 13 percent of around 1,037 start-ups in Indonesia can scale up their business, while most were reported to be stagnant or dissolved.Ride-hailing start-up giants Gojek and Grab have recently had to retire some of their non-core businesses because of the pandemic’s impact on the companies’ operations.Singapore-based Grab announced in June that it would lay off 360 people, just under 5 percent of its region-wide employees, because of the ongoing crisis. Not long after, Gojek did a headcount cut of 430 workers or around 9 percent of its total workforce, as the company aims to focus on its ride-hailing, food delivery, e-payment and logistics services.Fishery e-commerce start-up Aruna cofounder Utari Octavianty said during the webinar that she pivoted her business in just a week after Indonesia announced rising COVID-19 cases in the country.“Almost all of our products are for exports, but as our logistics were disrupted, we quickly marketed our goods to domestic consumers,” she said. “In times of uncertainty, we can learn to ride the wave.”Aruna recently received US$5.5 million in its latest funding round. The company also reported a 86 percent revenue growth in the first quarter of the year from the same period in 2019.“Start-ups that are negatively affected can look at the room for improvements in their company first. Not every start-up needs to immediately pivot their business,” Amvesindo chairman Jefri Sirait said at the same event.He went on to say that start-ups needed to maintain their liquidity and build runway, which is the calculation on how long a company can survive when income and expenses stay constant.Start-ups need to determine and leverage their competitive advantage at the beginning to become the basis or scalability in the future, according to Jefri.Some venture capital firms (VCs) will consolidate with other VCs to disburse funds amid the pandemic. However, some VCs may hold back their investment plan.“If your start-up has a good product and it needs cash, you can meet with investors, preferably your existing ones, to build up your survival rate,” Jefri said, adding that founders needed to stay prudent but also make quick decisions during this time.Meanwhile, former Jakarta deputy governor and entrepreneur Sandiaga Uno said he saw many start-ups emerge during the pandemic as a sign that Indonesian entrepreneurs could find opportunities in a crisis.He said start-ups could become another kind of “vaccine” as it can provide job opportunities amid a wave of layoffs caused by the pandemic.The government predicts that 2.9 million to 5.2 million workers could lose their jobs during the health crisis as almost all components of economic activities has fallen.“I think we are going to face a new start-up landscape and we won’t experience the pre-COVID situation. Times are changing anyway, and we need to innovate,” he said. “In the current situation, good things come to those who move.”Topics : Adrian advised start-ups in their early stages to focus on building their team and product-market fit, among other measures, while weathering the current situation.Meanwhile, start-ups in the growth stage should focus on scalability and profitability to survive the health crisis and possibly attract new investors.He added that to revive a start-up, founders must also first determine the underlying problem that started the company’s demise in the first place.“If the company is facing a systemic problem, then founders need to rethink their teams, hire new people and build the company up again,” he said. Industry players and venture capitalists have urged start-up founders to innovate and look for opportunities to survive the COVID-19 pandemic.An estimated 15 percent of the country’s start-ups were “severely affected” by the global health crisis between March and May, according to the Venture Capital and Start-Up Indonesia Association (Amvesindo). The figure had gone up to 25 percent by August and is projected to further increase as the pandemic progresses.“In every crisis, start-ups should look for new opportunities or entry points. For existing companies, you can pivot your business to stay resilient,” fintech start-up Investree founder Adrian Gunadi said during a webinar on Thursday.last_img read more

Oxx wary of Australia challenge

first_img Press Association John Oxx accepts Investec Derby favourite Australia is “tailor-made” to handle the demands of Epsom on June 7. Oxx is cautiously optimistic about his chances of adding to his Classic haul at Epsom, but accepts the Aidan O’Brien-trained Australia, third in the Newmarket Guineas, is the one to beat. He told the Irish Times: “The Guineas is traditionally always the best trial and the favourite looks tailor-made for the job at Epsom. “Apart from the Guineas, it’s hard to know which was the best trial, or if they were any good at all. “But the two trials for a Derby horse in Ireland are the Ballysax and the Derrinstown and I think the Derrinstown was a good race this year. “It’s true the owner isn’t into running no-hopers, and neither am I. “We think this is a colt worth sending to Epsom. He’s very well bred. “We can’t be sure about him staying the mile and a half but that isn’t the worst complaint. “You would rather that than going there with an out-and-out stayer. “Epsom is a test of stamina and speed.” center_img The Currabeg handler has won the Derby twice with Sinndar (2000) and Sea The Stars (2009) and this year saddles Ebanoran. The Aga Khan’s colt was first past the post in the Derrinstown Derby Trial at Leopardstown but subsequently demoted into second place. last_img read more

Active shooter and soft targets panel

first_imgStuart KaplanFormer FBI Agent and ProfilerMr. Kaplan is a former FBI Agent and profiler who has appeared on various newscasts related to issues of great public concern.He also is the Founder and President of KSGRMG and serves as Senior Managing Partner of the affiliated law firm of Kaplan Sconzo & Parker, P.A. Panelist WPB MayorKeith JamesMayor Keith James was sworn into office earlier this year and has since taken many steps to betterour community and keep us safe.Before he became mayor he was also involved in the community as a  business owner and lawyer who worked with many small and medium size businesses, and local residents, to help them achieve their dreams by guiding them through complex legal issues.His experience working with some of Florida’s top law firms and his Harvard education has served West Palm Beach and our residents well. With the recent tragedies in El Paso and Dayton school and students preparing to return to school,  850WFTL’s Karen Curtis hosts a special pop-up panel on school safety, soft targets, and whether or not West Palm Beach is ready for a potential active shooter.She will be joined by West palm Beach mayor Keith James, Fire Chief Diana Matty , the Palm Beach County School District Police Chief Frank Kitzerow, and a panel of experts will address how to identify and protect yourself from an active shooter.Find out if your child’s school is protected by an armed officer and whether bullet proof backpacks actually save lives.Join us on Facebook live Monday at 9:00am for the panel discussion. Hector DelgadoRetired Navy Seal and Federal Law Enforcement OfficerHector Delgado is a retired Navy Seall and Federal Law enforcement Officer.He has since created an active shooter notification system called ASR that can be used in schools, businesses, and other public areas. (AP Photo/Patrick Semansky)Frank KitzerowPalm Beach County Schools Police ChiefFrank Kitzerow is the Police Chief for the Palm Beach County School district. He will be talking about thesteps the school district has taken to help ensure the safety of students and school staff members as wellas steps we call all take ourselves to be better prepared in the case of an active shooter. Diana MattyWPB  Fire ChiefWest Palm Beach Fire Chief Diana Matty oversees all emergency response from hurricanes to mass casualty situations for the West Palm Beach Fire Rescue. Coming from a family of firefighters she also plans to increase training for firefighters to ensure their safety on the job.last_img read more

Always amongst the “runs”: Steve Smith punishes himself with 3km run after he fails…

first_imgImage Courtesy:Advertisement aj4zNBA Finals | Brooklyn Vs5aiWingsuit rodeo📽Sindre Ebf7( IG: @_aubreyfisher @imraino ) 42Would you ever consider trying this?😱aa42eCan your students do this? 🌚2sfx0Roller skating! Powered by Firework The No.1 ranked test batsman has made the habit of staying at the crease for long hours and in the process has notched up tons of runs since his return to international cricket. Steve Smith endured a rare failure against Pakistan in Brisbane and the batsman took it upon himself to serve a punishment by running a stretch of 3 kilometers.  Advertisement Image Courtesy: india TVSmith only had the chance to bat once against the visitors since the Aussies picked up a dominant innings victory to start their summer on fire. The former Aussie skipper was dismissed for only 4 at the Gabba by Yasir Shah.The batsman responded by deliberately missing the team bus at the end of the test and proceeded to run his way back to the team hotel from the ground. The distance which measures out to be 3 km, is part of Smith’s interesting self reward-punishment scheme which he has put in place. He said:Advertisement “I always punish myself when I get no runs, just like I reward myself when I score runs with a chocolate bar at the end of the night if I get a hundred,” he said. “So yeah, if I get no runs I always like to have a run or go to the gym or do something just to give myself a bit of a punishment,” One thing is evident, it is tough to keep Smith away from “runs” whether it be ones on the cricket field or off the field.Advertisement Read Also:Watch: Usman Khawaja produces an overenthusiastic coin toss in Marsh Cup finalIndian cricket honours 26/11 martyrs and victims in classy show on Twitter Advertisementlast_img read more